Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 10
2017 8
2018 21
2019 12
2020 24
2021 13
2022 8
2023 17
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes.
Jilani S, Saco JD, Mugarza E, Pujol-Morcillo A, Chokry J, Ng C, Abril-Rodriguez G, Berger-Manerio D, Pant A, Hu J, Gupta R, Vega-Crespo A, Baselga-Carretero I, Chen JM, Shin DS, Scumpia P, Radu RA, Chen Y, Ribas A, Puig-Saus C. Jilani S, et al. Nat Commun. 2024 Feb 9;15(1):1244. doi: 10.1038/s41467-024-45221-2. Nat Commun. 2024. PMID: 38336975 Free PMC article.
Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy.
Nowicki TS, Peters CW, Quiros C, Kidd CK, Kawakami M, Klomhaus AM, Baselga-Carretero I, Kaplan-Lefko P, Macabali MH, Perez Garcilazo I, Berent-Maoz B, Comin-Anduix B, Ribas A. Nowicki TS, et al. Cancer Immunol Res. 2023 Dec 1;11(12):1589-1597. doi: 10.1158/2326-6066.CIR-23-0577. Cancer Immunol Res. 2023. PMID: 37871333 Free PMC article.
ERK mediates interferon gamma-induced melanoma cell death.
Champhekar A, Heymans R, Saco J, Turon Font G, Gonzalez C, Gao A, Pham J, Lee J, Maryoung R, Medina E, Campbell KM, Karin D, Austin D, Damioseaux R, Ribas A. Champhekar A, et al. Mol Cancer. 2023 Oct 6;22(1):165. doi: 10.1186/s12943-023-01868-x. Mol Cancer. 2023. PMID: 37803324 Free PMC article.
Antitumor Immune Responses in B2M-Deficient Cancers.
Torrejon DY, Galvez M, Abril-Rodriguez G, Campbell KM, Medina E, Vega-Crespo A, Kalbasi A, Comin-Anduix B, Ribas A. Torrejon DY, et al. Cancer Immunol Res. 2023 Dec 1;11(12):1642-1655. doi: 10.1158/2326-6066.CIR-23-0139. Cancer Immunol Res. 2023. PMID: 37801341
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. VanderWalde A, et al. Nat Med. 2023 Sep;29(9):2278-2285. doi: 10.1038/s41591-023-02498-y. Epub 2023 Aug 17. Nat Med. 2023. PMID: 37592104 Free PMC article. Clinical Trial.
IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing.
Pan Y, Phillips JW, Zhang BD, Noguchi M, Kutschera E, McLaughlin J, Nesterenko PA, Mao Z, Bangayan NJ, Wang R, Tran W, Yang HT, Wang Y, Xu Y, Obusan MB, Cheng D, Lee AH, Kadash-Edmondson KE, Champhekar A, Puig-Saus C, Ribas A, Prins RM, Seet CS, Crooks GM, Witte ON, Xing Y. Pan Y, et al. Proc Natl Acad Sci U S A. 2023 May 23;120(21):e2221116120. doi: 10.1073/pnas.2221116120. Epub 2023 May 16. Proc Natl Acad Sci U S A. 2023. PMID: 37192158 Free PMC article.
102 results